Forum for Long-term Shareholders in Pharming Group (@PharmingForum) header
Forum for Long-term Shareholders in Pharming Group (@PharmingForum) profile picture

Transgenic Production Technology Platform: #Pharming's gepatenteerde technologieplatform; #Ruconest #rhC1INH #HAE; Ultra-rare disease #APDS: #Leniolisib

Nederland
Joined October 2015
Photo by Forum for Long-term Shareholders in Pharming Group (@PharmingForum)Photo by Forum for Long-term Shareholders in Pharming Group (@PharmingForum)Photo by Forum for Long-term Shareholders in Pharming Group (@PharmingForum)Photo by Forum for Long-term Shareholders in Pharming Group (@PharmingForum)Photo by Forum for Long-term Shareholders in Pharming Group (@PharmingForum)Photo by Forum for Long-term Shareholders in Pharming Group (@PharmingForum)Photo by Forum for Long-term Shareholders in Pharming Group (@PharmingForum)Photo by Forum for Long-term Shareholders in Pharming Group (@PharmingForum)Photo by Forum for Long-term Shareholders in Pharming Group (@PharmingForum)Photo by Forum for Long-term Shareholders in Pharming Group (@PharmingForum)
Pharming Group reports first quarter 2024 financial results and provides business update $PHAR
4
10
672
Pharming Group reports fourth quarter and full year 2023 financial results $PHAR
5
5
11
897
Pharming Group announces updated full year 2023 guidance and Joenja® U.S. launch update $PHAR
7
575
Pharming announces first patient dosed in pediatric clinical trial for children aged 1 to 6 years for leniolisib $PHAR
2
10
703
Pharming Group reports third quarter 2023 financial results $PHAR
2
11
695
Forum for Long-term Shareholders in Pharming Group retweeted
Beursblik: Van Lanschot Kempen zet Pharming op de kooplijst deaandeelhouder.nl/nieuws/20…
3
1
9
6,815
Pharming Group to participate in September investor conferences $PHAR
7
520
Pharming Group to convene Extraordinary General Meeting of Shareholders $PHAR
2
3
632
Pharming announces first patient enrolled in Phase III clinical trial of leniolisib for the treatment of APDS in Japan $PHAR
1
9
462
Pharming Group reports second quarter and first half 2023 financial results $PHAR
2
6
547
Pharming to nominate industry leader Dr. Richard Peters as new Chairman of the Board $PHAR
8
368
Pharming announces sale of priority review voucher $PHAR
1
1
5
856
Pharming Group reports on results of the 2023 Annual General Meeting of Shareholders $PHAR
1
3
554
Pharming Group reports financial results for the first quarter of 2023 $PHAR
2
2
8
692
Pharming to attend the H.C. Wainwright BioConnect Investor Conference 2023 $PHAR
5
375
Pharming to attend the Van Lanschot Kempen Life Sciences Conference 2023 $PHAR
1
7
457
Pharming announces the first commercial shipments of Joenja® (leniolisib) to patients in the U.S. $PHAR
2
2
1
17
984
#PharmingGroup $PHAR Weekoverzicht KW13 Open: 1,374; close: 1,225 (-10,84%) t.o.v. slot KW12: +23,05%; High: 1,374; low: 1,109; Volume: 154.674.800
5
402